Skip to main content
SpringerLink
Log in

Syndrome des ovaires polykystiques

  • Chapter
Physiologie, pathologie et thérapie de la reproduction chez l’humain

  • 921 Accesses

Résumé

Le syndrome des ovaires polykystiques (SOPK) a été initialement décrit en 1935 par Stein et Leventhal (1). Ce syndrome entraîne des répercussions aussi bien sur l’axe gonadotrope qu’au niveau métabolique et vasculaire. Il représente l’un des troubles hormonaux les plus fréquents chez la femme. Sa prévalence est estimée entre 5 et 10 % de la population féminine (2–4). La prévalence varie selon les populations, en raison probablement de l’origine ethnique et de facteurs environnementaux (5, 6). Le diagnostic de SOPK a fait l’objet de nombreuses discussions en raison de l’hétérogénéité des symptômes et de leur variabilité dans le temps.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Stein IF, Leventhal ML (1935) Amenorrhea associated with bilateral polycystic ovaries. J Obstet Gynecol 29:181–191

    Google Scholar 

  2. Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352:1223–1236

    Article  PubMed  CAS  Google Scholar 

  3. Knochenhauer E, Key TJ, Kahsar-Miller M et al. (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078–3082

    Article  PubMed  CAS  Google Scholar 

  4. Asuncion M, Calvo RM, San Millan JL et al. (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434–2438

    Article  PubMed  CAS  Google Scholar 

  5. Kauffman RP, Baker VM, DiMarino P et al. (2002) Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. J Obstet Gynecol 187:1362–1369

    Article  Google Scholar 

  6. Williamson K, Gunn A, Johnson N, Milsom SR(2001) The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust N Z J Obstet Gynaecol 41:202–206

    Article  PubMed  CAS  Google Scholar 

  7. Zawadski JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Polycystic Ovary Syndrome. Dunaif A, Givens JR, Haseltine F, eds. Boston: Blackwell Scientific: 377–384

    Google Scholar 

  8. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004 19:41–47

    Google Scholar 

  9. Laven JS, Imani B, Eijkemans MJ, Fauser BC (2002) New approaches to PCOS and other forms of anovulation. Obstet Gynecol Surv 57:755–767

    Article  PubMed  Google Scholar 

  10. Slayden SM, Moran C, Sams Jr WMet al. (2002) Hyperandrogenemia in patients presenting with acne. Fertil Steril 75:889–892

    Article  Google Scholar 

  11. Moran C, Knochenhauer E, Boots LR, Azziz R (1999) Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril 71:671–674

    Article  PubMed  CAS  Google Scholar 

  12. Fauser BC, Pache TD, Lamberts SW et al. (1991) Serum bioactive and immunoreactive LH and FSH levels in women with cycle abnormalities, with or without PCOD. J Clin Endocrinol Metab 73:811–817

    Article  PubMed  CAS  Google Scholar 

  13. Waldstreicher J, Santoro NF, Hall HJ et al. (1988) Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence of partial gonadotroph desensitization. J Clin Endocrinol Metab 66:165–172

    Article  PubMed  CAS  Google Scholar 

  14. Azziz R, Hincapie LA, Knochenhauer ES et al. (1999) Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 72:915–925

    Article  PubMed  CAS  Google Scholar 

  15. Balen AH, Laven JS, Tan SL, Dewailly D (2003) Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9:505–514

    Article  PubMed  Google Scholar 

  16. Bucket WM, Bouzayen R, Watkin KL et al. (2003) Ovarian stromal echogenicity in women with normal and polycystic ovaries. Hum Reprod 18:598–603

    Article  Google Scholar 

  17. Dewailly D, Robert Y, Helin I et al. (1994) Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol (Oxf) 41:557–562

    Article  CAS  Google Scholar 

  18. National Cholesterol Education Program (NCEP) Expert Panel on Detection (2002). Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421

    Google Scholar 

  19. Rowe PJ, Comhaire FH, Hargreave TB (2000) Female partner. In: WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Cambridge University Press 40–67

    Google Scholar 

  20. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165–1174

    Article  PubMed  CAS  Google Scholar 

  21. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E (2001). Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). J Physiol Endocrinol Metab 281:392–399

    Google Scholar 

  22. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18:774–800

    Article  PubMed  CAS  Google Scholar 

  23. Legro RS, Finegood D, Dunaif A (1998) A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:2694–2698

    Article  PubMed  CAS  Google Scholar 

  24. Legro RS, Castracane VD, Kauffman RP (2004) Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59:141–154

    Article  PubMed  Google Scholar 

  25. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G (2004) Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:1273–1276

    Article  PubMed  CAS  Google Scholar 

  26. Nestler JE, Powers LP, Matt DW et al. (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83–89

    Article  PubMed  CAS  Google Scholar 

  27. Ehrmann DA, Barnes RB, Rosenfield RL et al. (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146

    Article  PubMed  CAS  Google Scholar 

  28. Legro RS, Kunselman AR, Dodson WC, Dunaif A(1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169

    Article  PubMed  CAS  Google Scholar 

  29. O’Meara NM, Blackman JD, Ehrmann DA et al. (1999) Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76:1241–1247

    Article  Google Scholar 

  30. Dunaif A, Finegood DT (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942–947

    Article  PubMed  CAS  Google Scholar 

  31. Ehrmann DA, Sturis J, Byrne MM et al. (1995) Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96:520–527

    Article  PubMed  CAS  Google Scholar 

  32. Norman RJ, Masters L, Milner CR et al. (2001) Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome. Hum Reprod 9:1995–1998

    Article  Google Scholar 

  33. Glueck CJ, Wang P, Kobayashi S et al. (2002) Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 77:520–525

    Article  PubMed  CAS  Google Scholar 

  34. Glueck CJ, Papanna R, Wang P et al. (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52:908–915

    Article  PubMed  CAS  Google Scholar 

  35. Dahlgren E, Janson PO, Johansson S et al. (1992) Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71:599–604

    Article  PubMed  CAS  Google Scholar 

  36. Orio Jr. F, Palomba S, Cascella T et al. (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:4588–4593

    Article  PubMed  CAS  Google Scholar 

  37. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M (2002) Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 87:3871–3875

    Article  PubMed  CAS  Google Scholar 

  38. Orio Jr. F, Palomba S, Spinelli L et al. (2004) The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89:3696–3701

    Article  PubMed  CAS  Google Scholar 

  39. Talbott E, Guzick D, Clerici A et al. (1995) Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821–826

    Article  PubMed  CAS  Google Scholar 

  40. Wild S, Pierpoint T, Jacobs H, McKeigue P (2000) Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil 3:101–105

    Article  Google Scholar 

  41. Legro RS (2003) Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24:302–312

    Article  PubMed  Google Scholar 

  42. Vgontzas AN, Legro RS, Bixler EO et al. (2001) Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 86:517–520

    Article  PubMed  CAS  Google Scholar 

  43. Fogel RB, Malhotra A, Pillar Get al. (2001) Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 86:1175–1180

    Article  PubMed  CAS  Google Scholar 

  44. Gopal M, Duntley S, Uhles M, Attarian H (2002) The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovary syndrome. Sleep Med 3:401–404

    Article  PubMed  Google Scholar 

  45. Hardiman P, Pillay OC, Atiomo W (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361:1810–1812

    Article  PubMed  Google Scholar 

  46. Balen A (2001) Polycystic ovary syndrome and cancer. Hum Reprod Update 7:522–525

    Article  PubMed  CAS  Google Scholar 

  47. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ et al. (2003) A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88:1927–1932

    Article  PubMed  CAS  Google Scholar 

  48. Golland IM, Elstein ME (1993) Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann N Y Acad Sci 687:263–271

    Article  PubMed  CAS  Google Scholar 

  49. Guido M, Romualdi D, Giuliani M et al. (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89:2817–2823

    Article  PubMed  CAS  Google Scholar 

  50. Huber-Buchholz MM, Carey DG, Norman RJ (1999) Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84:1470–1474

    Article  PubMed  CAS  Google Scholar 

  51. Hoeger KM, Kochman L, Wixom N et al. (2004) A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82:421–429

    Article  PubMed  CAS  Google Scholar 

  52. Crosignani PG, Colombo M, Vegetti W et al. (2003) Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 18:1928–1932

    Article  PubMed  Google Scholar 

  53. Goodyear LJ, Kahn BB (1998) Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49:235–261

    Article  PubMed  CAS  Google Scholar 

  54. Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403

    Article  PubMed  CAS  Google Scholar 

  55. The Thessaloniki ESHRE/ASRM-sponsored PCOS Consensus Worhshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89:505–522

    Article  Google Scholar 

  56. Beck JI, Boothroyd C, Proctor M et al. (2005) Oral antiestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev (CD002249)

    Google Scholar 

  57. Imani B, Eijkemans MJ, Te Velde ER et al. (1998) Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotrophic oligomenorrheic infertility. J Clin Endocrinol Metab 83:236–265

    Article  Google Scholar 

  58. Imani B, Eijkemans MJ, Te Velde ER et al. (2000) Free, rogen index and leptin are the most prominent endocrine predictors of ovarian during clomiphene citrate induction of ovulation in normogonadotrophic oligomenorrheic infertility. J Clin Endocrinol Metab 85:676–682

    Article  PubMed  CAS  Google Scholar 

  59. Imani B, Eijkemans MJ, Te Velde ER et al. (1999) Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotrophic oligomenorrheic infertility. J Clin Endocrinol Metab 84:1617–1622

    Article  PubMed  CAS  Google Scholar 

  60. Branigan EF, Estes MA (2003) A randomized clinical trial of treatment of clomiphene citrate-resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment. J Obstet Gynecol 188:1424–1428

    Article  CAS  Google Scholar 

  61. Klip A, Leiter LA (1990) Cellular mechanism of action of metformin. Diabetes Care 13:696–704

    Article  PubMed  CAS  Google Scholar 

  62. Mansfield R, Galea R, Brincat M et al. (2003) Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 79:956–962

    Article  PubMed  Google Scholar 

  63. Attia GR, Rainey WE, Carr BR (2001) Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 76:517–524

    Article  PubMed  CAS  Google Scholar 

  64. Crave JC, Fimbel S, Lejeune H et al. (1995) Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80:2057–2062

    Article  PubMed  CAS  Google Scholar 

  65. Kashyap S, Wells GA, Rosenwaks Z (2004) Insulin-sensitizing agents as primary therapy for patients with polycystic ovary syndrome. Hum Reprod 19:2474–2483

    Article  PubMed  CAS  Google Scholar 

  66. Lord JM, Flight IH, Norman RJ (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327:951–956

    Article  PubMed  CAS  Google Scholar 

  67. Palomba S, Orio Jr. F, Falbo A et al. (2005) Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:4068–4074

    Article  PubMed  CAS  Google Scholar 

  68. Moll E, Bossuyt PM, Korevaar JC et al. (2006) Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332:1485

    Article  PubMed  CAS  Google Scholar 

  69. Legro RS, Barnhart HX, Schlaff WD et al. (2007) Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356:551–566

    Article  PubMed  CAS  Google Scholar 

  70. Morin-Papunen LC, Koivunen RM, Tomas C et al. (1998) Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:2566–2568

    Article  PubMed  CAS  Google Scholar 

  71. Baillargeon JP, Jakubowicz DJ, Iuorno MJ et al. (2004) Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82:893–902

    Article  PubMed  CAS  Google Scholar 

  72. Kjotrod SB, von During V, Carlsen SM (2004) Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome: a prospective, randomized, double blind study. Hum Reprod 19:1315–1322

    Article  PubMed  CAS  Google Scholar 

  73. Jakubowicz DJ, Iuorno MJ, Jakubowicz S et al. (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87:524–529

    Article  PubMed  CAS  Google Scholar 

  74. Glueck CJ, Phillips H, Cameron D et al. (2001) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 75:46–52

    Article  PubMed  CAS  Google Scholar 

  75. Seto-Young D, Paliou M, Schlosser J et al. (2005) Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 90:6099–6105

    Article  PubMed  CAS  Google Scholar 

  76. Azziz R, Ehrmann D, Legro RS et al. (2001) Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626–1632

    Article  PubMed  CAS  Google Scholar 

  77. Sepilian V, Nagamani M (2005) Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 90:60–65

    Article  PubMed  CAS  Google Scholar 

  78. Belli SH, Graffigna MN, Oneto A et al. (2004) Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 81:624–629

    Article  PubMed  CAS  Google Scholar 

  79. Badawy A, Abdel Aal I, Abulatta M (2009) Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril 92:849–852

    Article  PubMed  CAS  Google Scholar 

  80. Badawy A, Abdel Aal I, Abulatta M (2009) Clomiphene citrate or anastrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective controlled trial. Fertil Steril 92:860–863.

    Article  PubMed  CAS  Google Scholar 

  81. Ganesh A, Goswamy SK, Chattopadhyay R et al. (2009) Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial. J Assist Reprod Genet 26:19–24

    Article  PubMed  Google Scholar 

  82. Fauser BC, Van Heusden AM (1997) Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 18:71–106

    Article  PubMed  CAS  Google Scholar 

  83. Mulders A, Eijkemans MJ, Imani B, Fauser BC (2003) Prediction of chances for success or complications in gonadotropin ovulation induction in normogonadotropic anovulatory infertility. RBM Online 7:170–178

    PubMed  Google Scholar 

  84. Imani B, Eijkemans MJ, Faessen GH et al. (2002) Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril 77:83–90

    Article  PubMed  Google Scholar 

  85. Homburg R, Howles CM (1999) Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 5:493–499

    Article  PubMed  CAS  Google Scholar 

  86. Christin-Maître S, Hugues JN, Recombinant FSH Study Group (2003) A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 18:1626–1631

    Article  PubMed  Google Scholar 

  87. Hugues JN, Cedrin-Durnerin I, Avril C et al. (1996) Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome. Hum Reprod 11:2581–2584

    PubMed  CAS  Google Scholar 

  88. Palomba S, Falbo A, Orio Jr. F et al. (2005) A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 20:2879–2886

    Article  PubMed  CAS  Google Scholar 

  89. Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P (2007) Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 3: CD001122

    Google Scholar 

  90. Watrelot A, Dreyfus JM, Andine JP(1999) Evaluation of the performance of fertiloscopy in 160 consecutive infertile patients with no obvious pathology. Hum Reprod 14:707–711

    Article  PubMed  CAS  Google Scholar 

  91. Fernandez H, Alby JD, Gervaise A et al. (2001) Operative transvaginal hydrolaparoscopy for treatment of polycystic ovary syndrome: a new minimally invasive surgery. Fertil Steril 75:607–611

    Article  PubMed  CAS  Google Scholar 

  92. Amer SA, Li TC, Cooke ID (2003) A prospective dose-finding study of the amount of thermal energy required for laparoscopic ovarian diathermy. Hum Reprod 18:1 693–1 698

    Article  CAS  Google Scholar 

  93. Malkawi HY, Qublan HS, Hamaideh AH (2003) Medical vs. surgical treatmentfor clomiphene citrate-resistant women with polycystic ovarysyndrome. J Obstet Gynaecol 23:289–293

    Article  PubMed  CAS  Google Scholar 

  94. Rimington MR, Walker SM, Shaw RW (1997) The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum Reprod 12:1443–1447

    Article  PubMed  CAS  Google Scholar 

  95. Balen A (2006) Surgical management of PCOS Best Pract Res Clin Endocrinol Metab 20:271–280

    Google Scholar 

  96. Campo S (1998) Ovulatory cycles, pregnancy outcome and complications after surgical treatment of polycystic ovary syndrome. Obstet Gynecol Surv 53:297–308

    Article  PubMed  CAS  Google Scholar 

  97. Bayram N, van Wely M, Kaaijk EM et al. (2004) Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 328:192

    Article  PubMed  CAS  Google Scholar 

  98. Lazovic G, Milacic D, Terzic M et al. (1998) Medicaments or surgical therapy of PCOS. Fertil Steril 70 (Suppl):S472

    Google Scholar 

  99. Farquhar CM, Williamson K, Gudex G et al. (2002) A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 78:404–411

    Article  PubMed  Google Scholar 

  100. Kaya H, Sezik M, Ozkaya O (2005) Evaluation of a new surgical approach for the treatment of clomiphene citrate-resistant infertility in polycystic ovary syndrome: laparoscopic ovarian multi-needle intervention. J Minim Invasive Gynecol 12:355–358

    Article  PubMed  Google Scholar 

  101. Vegetti W, Ragni G, Baroni E et al. (1998) Laparoscopic ovarian versus low-dose pure FSH in anovulatory clomiphene-resistant patients with polycystic ovarian syndrome: randomized prospective study [abstract]. Hum Reprod 13:120

    Article  Google Scholar 

  102. Farquhar CM, Williamson K, Brown PM, Garland J (2004) An economic evaluation of laparoscopic ovarian diathermy versus gonadotrophin therapy for women with clomiphene citrate resistant polycystic ovary syndrome. Hum Reprod 19:1110–1115

    Article  PubMed  Google Scholar 

  103. van Wely M, Bayram N, van der Veen F, Bossuyt PM (2004) An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod 19:1741–1745

    Article  PubMed  CAS  Google Scholar 

  104. Amer SA, Li TC, Ledger WL (2004) Ovulation induction using laparoscopic ovarian drilling in women with polycystic ovarian syndrome: predictors of success. Hum Reprod 19:1719–1724

    Article  PubMed  CAS  Google Scholar 

  105. Palomba S, Orio Jr F, Nardo LG et al. (2004) Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 89:4801–4809

    Article  PubMed  CAS  Google Scholar 

  106. Cohen J, Audebert A (1989) De la «mécanique» au fonctionnel: place des traitements chirurgicaux. In: Dystrophies ovariennes. Paris, Masson 183–192

    Google Scholar 

  107. Gurgan T, Urman B, Aksu T et al. (1992) The effect of short-interval laparoscopic lysis of adhesions on pregnancy rates following Nd-YAG laser photocoagulation of polycystic ovaries. Obstet Gynecol 80:45–47

    PubMed  CAS  Google Scholar 

  108. Greenblatt EM, Casper RF (1993) Adhesion formation after laparoscopic ovarian cautery for polycystic ovarian syndrome: lack of correlation with pregnancy rate. Fertil Steril 60:766–770

    PubMed  CAS  Google Scholar 

  109. Amer SA, Banu Z, Li TC, Cooke ID (2002) Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum Reprod 17:2851–2857

    Article  PubMed  CAS  Google Scholar 

  110. Kaaijk EM Hamerlynck JV Beek JF van der Veen 1999 Clinical outcome after unilateral oophorectomy in patients with polycystic ovary syndrome. Hum Reprod 14889–892

    Google Scholar 

  111. Cohlen BJ, Vandekerckhove P, de Velde ER, Habbema JD (2000) Timed intercourse versus intra-uterine insemination with or without ovarian hyperstimulation for subfertility in men. Cochrane Database Syst Rev 2: CD000360

    Google Scholar 

  112. Gerli S, Casini ML, Unfer Vet al. (2004) Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles: a prospective, randomized analysis of cost effectiveness. Fertil Steril 82:573–578

    Article  PubMed  CAS  Google Scholar 

  113. Mitwally MF, Casper RF (2004) Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 11:406–415

    Article  PubMed  CAS  Google Scholar 

  114. Palomba S, Falbo A, Orio F Jr et al. (2005) A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum Reprod 20:2879–2886

    Article  PubMed  CAS  Google Scholar 

  115. Heijnen EM, Eijkemans MJ, De Klerk C et al. (2007) A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 369:743–749

    Article  PubMed  Google Scholar 

  116. Damario MA, Barmat L, Liu HC et al. (1997) Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 12:2359–2365

    Article  PubMed  CAS  Google Scholar 

  117. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM (2006) GnRH-antagonists in ovarianstimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13:628–638

    Article  PubMed  CAS  Google Scholar 

  118. Kolibianakis E, Zikopoulos K, Albano C et al. (2003) Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. Reprod Biomed Online 7:313–318

    Article  PubMed  CAS  Google Scholar 

  119. Heijnen EM, Eijkemans MJ, Hughes EG et al. (2006) A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 12:13–21

    Article  PubMed  CAS  Google Scholar 

  120. Tang T, Glanville J, Orsi N et al. (2006) The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 21:1416–1425

    Article  PubMed  CAS  Google Scholar 

  121. Hwang JL, Seow KM, Lin YH et al. (2005) IVF versus ICSI in sibling oocytes from patients with polycystic ovarian syndrome: a randomized controlled trial. Hum Reprod 20:1261–1265

    Article  PubMed  Google Scholar 

  122. Child TJ, Phillips SJ, Abdul-Jalil AK et al. (2002) A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 100:665–670

    Article  PubMed  Google Scholar 

  123. Chian RC, Buckett WM, Tan SL (2004) In-vitro maturation of human oocytes. Reprod Biomed Online 8:148–166

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de médecine de la reproduction, Hôpital Jean Verdier (APHP), Avenue du 14-Juillet, 93140, Bondy

    J.-N. Hugues

Authors
  1. J.-N. Hugues
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Hugues, JN. (2011). Syndrome des ovaires polykystiques. In: Physiologie, pathologie et thérapie de la reproduction chez l’humain. Springer, Paris. https://doi.org/10.1007/978-2-8178-0061-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0061-5_17

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0060-8

  • Online ISBN: 978-2-8178-0061-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation